ARTICLE | Clinical News
ApoGraft: Ph I/II ApoGraft01 ongoing
April 20, 2017 9:50 PM UTC
An independent DSMB approved the enrollment of the next 2 patients in the first cohort of the open-label, Israeli Phase I/II ApoGraft01 trial evaluating transplanted ApoGraft exposed to FASL. The DSMB...
BCIQ Company Profiles